Hancock Jaffe Laboratories Inc (OQ:HJLI)

Apr 07, 2021 01:40 pm ET
First U.S. Patent Issues on Hancock Jaffe VenoValve
IRVINE, CA / ACCESSWIRE / April 7, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the United States Patent and Trademark Office (USPTO) has issued the first patent covering the company's VenoValve. The patent is entitled Implantable Vein Frame and is U.S. patent number 10,959,841.
Apr 05, 2021 07:30 am ET
Hancock Jaffe Receives IDE Approval To Begin VenoValve U.S. Pivotal Trial
IRVINE, CA / ACCESSWIRE / April 5, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational Device Exemption (IDE) application to begin the U.S. pivotal trial for the VenoValve®. The VenoValve is an implantable valve designed to restore proper directional blood flow for patients with Chronic Venous Insufficiency (C
Mar 08, 2021 08:30 am ET
Hancock Jaffe Submits IDE Application to FDA for VenoValve U.S. Pivotal Trial
IRVINE, CA / ACCESSWIRE / March 8, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) seeking approval to begin a U.S. pivotal trial for the VenoValve®. The VenoValve is an implantable valve designed to restore proper directional blood flow for patients with Chronic Venous In
Feb 24, 2021 12:05 pm ET
First U.S. Patent Allowed on Hancock Jaffe VenoValve
Company Receives Notice of Allowance from U.S. Patent and Trademark Office
Feb 11, 2021 04:05 pm ET
Hancock Jaffe Completes $41 Million Public Offering
Capital Raise to Fund VenoValve U.S. Pivotal Trial
Feb 09, 2021 08:30 am ET
Hancock Jaffe Laboratories Announces Pricing of Upsized $36 Million Offering
IRVINE, CA / ACCESSWIRE / February 9, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced the pricing of its upsized underwritten public offering of units for gross proceeds of approximately $36 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the company.
Jan 12, 2021 08:30 am ET
Hancock Jaffe Concludes Successful VenoValve Pre-IDE Meeting with FDA
Company to Move Forward with Application for VenoValve U.S. Pivotal Trial
Dec 30, 2020 04:15 pm ET
Hancock Jaffe Announces Executive Promotions
IRVINE, CA / ACCESSWIRE / December 30, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Dr. Hamed Alavi has been promoted to Vice President of Research and Development and Quality and that Craig Glynn has accepted the position of Chief Financial Officer.
Dec 21, 2020 08:30 am ET
Hancock Jaffe Deemed Compliant With All NASDAQ Continued Listing Requirements
Company Regains Compliance with NASDAQ Minimum Bid Requirement
Dec 16, 2020 08:30 am ET
Hancock Jaffe Reports Two CoreoGraft Patients Have Reached 30 Day Milestone
Electrocardiograms Indicate Good Cardiac Function for Both Patients
Dec 15, 2020 04:15 pm ET
Dec 14, 2020 08:30 am ET
Hancock Jaffe Announces One Year Follow-up Data on Eleventh VenoValve Patient
Final Patient in First-in-Human Study Shows Significant Improvement at One Year
Dec 10, 2020 08:30 am ET
Dec 01, 2020 08:30 am ET
Hancock Jaffe Announces One Year Follow-up Data on Tenth VenoValve Patient
Patient Shows Significant Improvement at One Year
Nov 30, 2020 08:31 am ET
Thinking about buying stock in Hancock Jaffe, Oramed Pharmaceuticals, Tilray, Hexo Corp, or Arbutus Biopharma?
NEW YORK, Nov. 30, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HJLI, ORMP, TLRY, HEXO, and ABUS.
Nov 27, 2020 08:30 am ET
Hancock Jaffe Announces Reverse Stock Split
IRVINE, CA / ACCESSWIRE / November 27, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1 for 25 (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 12:01 a.m. Eastern time on November 30, 2020 and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis on November 30, 2020 under the C
Nov 23, 2020 08:30 am ET
Hancock Jaffe's VenoValve(R) Results Featured in Journal of Vascular Surgery Venous and Lymphatic Disorders
Preliminary First-in-Human Study Results Published in Peer-Reviewed Journal
Nov 05, 2020 01:45 pm ET
Oct 28, 2020 08:30 am ET
Hancock Jaffe Reports Successful Completion of First CoreoGraft Heart Bypass Surgery
First CoreoGraft Recipient Discharged from the Hospital
Oct 27, 2020 08:30 am ET
Oct 21, 2020 12:15 pm ET
Hancock Jaffe Announces One Year Follow-up Data on Ninth VenoValve Patient
Patient Continues to Show Significant Improvement at One Year
Oct 14, 2020 08:30 am ET
Hancock Jaffe to Begin CoreoGraft First-in-Human Study
First Two Surgeries Scheduled to Take Place by End of October
Oct 08, 2020 08:30 am ET
Oct 07, 2020 08:30 am ET
Hancock Jaffe Laboratories, Inc. Announces Pricing of $5.1 Million Registered Direct Offering Priced at the Market
IRVINE, CA / ACCESSWIRE / October 7, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced the pricing of a registered direct offering of $5.1 million of its common stock and warrants to purchase shares of common stock in a concurrent private placement. The combined purchase price for one share of common stock and one warrant to purchase one share of common stock will be $0.535 which is priced at-the-market under Nasdaq rules.
Sep 21, 2020 08:30 am ET
Aug 25, 2020 11:00 am ET
Aug 21, 2020 08:30 am ET
Hancock Jaffe Announces One Year Follow-up Data on Two Additional VenoValve Patients
VenoValve Patients Continue to Show Significant Improvement at One Year
Aug 10, 2020 08:30 am ET
Hancock Jaffe Regains Compliance with Nasdaq Stockholder's Equity Rule
IRVINE, CA / ACCESSWIRE / August 10, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that HJLI has received formal notification from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has evidenced full compliance with the stockholders' equity requirement for the continued listing of its shares on The Nasdaq Capital Market and, as a result, the equity compliance matter previously considered by the Nasdaq Hearings Panel (the "Panel") has been closed.
Jul 23, 2020 08:30 am ET
Hancock Jaffe Receives Permission to Proceed with First-in-Human CoreoGraft Study
Patient Selection to Begin Immediately for CoreoGraft Study
Jul 21, 2020 04:01 pm ET
Hancock Jaffe Laboratories Announces Closings of $6.2 Million Offerings Including Full Exercise of Over-Allotment Option
IRVINE, CA / ACCESSWIRE / July 21, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced the closings of an underwritten public offering, the full exercise of the underwriter's over-allotment option, and a private placement, for total gross proceeds of approximately $6.2 million, prior to deducting underwriting discounts, placement agent fees, and offering expenses.
Jul 17, 2020 09:40 am ET
Hancock Jaffe Laboratories Announces Pricing of $5.6 Million Offering
IRVINE, CA / ACCESSWIRE / July 17, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced the pricing of a $5.6 million offering, which consisted of an underwritten public offering of units and a private placement of units for gross proceeds of approximately $5.6 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the company.
Jun 01, 2020 02:45 pm ET
Hancock Jaffe Announces Registered Direct Offering Priced At Market
IRVINE, CA / ACCESSWIRE / June 1, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $1.333 million of its common stock in a registered direct offering and warrants to purchase shares of common stock in a concurrent private placement. The combined purchase price for one share of common stock and one warrant to purchase one share of common stock will b
Jun 01, 2020 08:30 am ET
Hancock Jaffe Announces Intention to Merge with Catheter Precision
Companies Sign Non-Binding Letter of Intent to Merge
May 12, 2020 08:30 am ET
Hancock Jaffe Announces Plans for CoreoGraft First-in-Human Study
CoreoGraft Study Approved by the Superintendent of Health of the National Health Council of Paraguay
Apr 28, 2020 10:30 am ET
Hancock Jaffe Announces One Year Follow-up Data on VenoValve Patients
VenoValve Patients Continue to Show Significant Improvement at One Year
Apr 27, 2020 08:31 am ET
Hancock Jaffe Announces Registered Direct Offering
IRVINE, CA / ACCESSWIRE / April 27, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $1 million of its common stock in a registered direct offering and warrants to purchase shares of common stock in a concurrent private placement. The combined purchase price for one share of common stock and one warrant to purchase one share of common stock will be
Mar 05, 2020 08:31 am ET
Feb 26, 2020 08:30 am ET
Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa to Present Updated VenoValve Data Next Week at the 32nd Annual Meeting of the American Venous Forum
Updated VenoValve data will include 8 Patients at 180 days - including 1 Patient at 365 Days Post VenoValve Surgery
Jan 08, 2020 08:31 am ET
Dec 20, 2019 08:31 am ET
VenoValve Abstract Published in January 2020 Edition of Journal of Vascular Surgery
Presentation from Abstract to be Delivered at the Southern Association of Vascular Surgery Conference January 8 to 11 in Palm Beach, Florida
Nov 15, 2019 01:00 pm ET
Hancock Jaffe Enrolls and Successfully Implants Tenth VenoValve Patient
Initial Implantation Phase for First-in-Man Study Now Completed
Oct 22, 2019 01:00 pm ET
Principal Investigator Dr. Jorge Hernando Ulloa to Present VenoValve Six Month Data at the 20th Congress of Asian Society for Vascular Surgery on October 25, 2019
IRVINE, CA / ACCESSWIRE / October 22, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that on Friday October 25, 2019, Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI's first-in-man VenoValve® study in Bogota, Colombia, will present six month data on the VenoValve at the 20th Congress of Asian Society for Vascular Surgery. Dr. Ulloa's presentation is entitled Prosthetic Venous Valve for Post-Thrombotic Syndrome.
Oct 14, 2019 12:15 pm ET
Hancock Jaffe to Present at the Inaugural MicroCap Rodeo Investor Conference on October 16, 2019
IRVINE, CA / ACCESSWIRE / October 14, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, has been invited to present at the inaugural MicroCap Rodeo Investor Conference on October 16, 2019 in Austin.
Sep 26, 2019 08:31 am ET
Hancock Jaffe to Host Virtual Roadshow Webinar on Thursday, October 3, 2019 at 4:30 p.m. Eastern Time
IRVINE, CA / ACCESSWIRE / September 26, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, will host a virtual roadshow webinar on October 3, 2019 at 4:30 p.m. Eastern time.
Aug 29, 2019 08:31 am ET
Aug 20, 2019 08:31 am ET
Jul 26, 2019 08:31 am ET
Principle Investigator Dr. Jorge Hernando Ulloa Reports New 90 Day VenoValve Data at the Second Annual Society of Vascular and Endovascular Surgery Congress of Central America and the Caribbean
The meeting of the Society of Vascular and Endovascular Surgery of Central America and the Caribbean was hosted by the Society of Vascular and Endovascular Surgery of the Dominican Republic, in Santo Domingo. The conference focuses on the most recent technological advances in vascular and endovascular surgery and is aimed at specialists in vascular and cardiovascular medicine, as well as dermatologists, radiologists, vascular sonographers, nephrologists, cardiologists and family doctors.
Jul 19, 2019 08:31 am ET
Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa to Present New 90 Day VenoValve Data at the Second Annual Society of Vascular and Endovascular Surgery Congress of Central America and the
The meeting of the Society of Vascular and Endovascular Surgery of Central America and the Caribbean is being hosted by the Society of Vascular and Endovascular Surgery of the Dominican Republic, in Santo Domingo. The conference focuses on the most recent technological advances in vascular and endovascular surgery and is aimed at specialists in vascular and cardiovascular medicine, as well as dermatologists, radiologists, vascular sonographers, nephrologists, cardiologists and family doctors.
Jun 27, 2019 08:30 am ET
Jun 24, 2019 11:00 am ET
Primary Investigator Dr. Jorge Hernando Ulloa Reports New and Updated VenoValve Data at C3 Global Conference
Clinical Manifestations of CVI Improved an Average of 46% Across All Five VenoValve Patients
Jun 20, 2019 08:31 am ET
Hancock Jaffe Hires Brian Roselauf as Director of Research and Development
IRVINE, CA / ACCESSWIRE / June 20, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, today announced that Brian Roselauf will be joining the company as its Director of Research and Development. Mr. Roselauf will join Hancock Jaffe on June 24, 2019, and will initially focus on design verification and validation activities to prepare for the filing of the Investigational Device Exemption ("IDE") application for the U.S. pivotal trial for HJLI's VenoValve.
Jun 13, 2019 08:31 am ET
Jun 12, 2019 09:00 am ET
Hancock Jaffe Announces Pricing of Public Offering of Common Stock
Company Fortifies Balance Sheet Ahead of Key Milestones
Jun 07, 2019 08:31 am ET
Hancock Jaffe Reports Early Positive Results from First-In-Human VenoValve Study
Reflux Significantly Reduced in Four out of Five Patients
Jun 03, 2019 08:31 am ET
Hancock Jaffe Enrolls Two Additional Patients for First-in-Human VenoValve Study
Implantations Expected to Take Place Later this Month
May 28, 2019 08:31 am ET
Hancock Jaffe to Present VenoValve Case Management Report at Expert Venous Management Conference on June 7, 2019
Initial Patient Data to be Released on June 7th for First-In-Human VenoValve Study
May 24, 2019 08:31 am ET
Hancock Jaffe Announces Retirement of Board Chairman Yury Zhivilo
IRVINE, CA / ACCESSWIRE / May 24, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, has announced that its Chairman, Yury Zhivilo, is retiring from its board of directors.
May 21, 2019 08:31 am ET
Hancock Jaffe Expands CoreoGraft Feasibility Study
Longer-Term Phase of the Trial Started with Additional Test Subjects
May 01, 2019 08:31 am ET
Hancock Jaffe Announces Successful Third Implantation for CoreoGraft Study at Texas Heart Institute
All Three Test Subjects for the Feasibility Study Have Now Been Successfully Implanted
Apr 30, 2019 08:31 am ET
Hancock Jaffe Mourns the Loss of Director Marc Robins
IRVINE, CA / ACCESSWIRE / April 30, 2019 / Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announces the passing of its director, Marc Robins. Mr. Robins passed away from complications from chronic venous insufficiency.
Apr 11, 2019 08:31 am ET
Mar 21, 2019 08:31 am ET
Hancock Jaffe Enrolls Four Additional Patients for First-in-Human VenoValve Study
Implantations to Take Place by End of April with Initial Data Expected in June 2019
Mar 18, 2019 08:31 am ET
Hancock Jaffe Announces Successful Start to CoreoGraft Study at Texas Heart Institute
Excellent Initial Flow Rates Achieved with CoreoGrafts for Bypasses Completed in Two Test Subjects
Mar 13, 2019 08:55 am ET
Hancock Jaffe Completes $2.7 Million Private Placement of Common Stock
Company Strengthens Financial Position Ahead of Key Milestones
Feb 19, 2019 08:31 am ET
Hancock Jaffe Successfully Starts First-in-Human VenoValve Study
Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a Company specializing in medical devices that restore cardiac and vascular health, today announced the successful start of its VenoValve® first-in-human study in Bogota, Colombia. The first...
Jan 28, 2019 08:00 am ET
Hancock Jaffe Announces Objectives for Upcoming CoreoGraft Study
Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a Company specializing in medical devices that restore cardiac and vascular health, today announced its objectives for its upcoming CoreoGraft® study at the Texas Heart Institute. The study...
Jan 15, 2019 08:00 am ET
Dr. Marc H. Glickman to Present at 6th Israeli Vascular Access Conference
Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a Company specializing in medical devices that restore cardiac and vascular health, today announced that Dr. Marc H. Glickman, HJLI's Chief Medical Officer, will be presenting at the 6th...
Jan 09, 2019 08:00 am ET
Hancock Jaffe Announces End Points for First-in-Human VenoValve Study
Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a Company specializing in medical devices that restore cardiac and vascular health, today announced end-points for its upcoming VenoValve first-in-human study in Bogota, Colombia. Endpoints...
Dec 17, 2018 08:00 am ET
Hancock Jaffe Receives Approval for First-in-Human VenoValve Study
Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, announced today that it has received regulatory approval from INVIMA, the Colombian equivalent of the U.S....
Dec 04, 2018 08:00 am ET
Hancock Jaffe Announces January CoreoGraft Study at the Texas Heart Institute
Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, announced today that it will begin a feasibility study for its CoreoGraft bioprosthetic graft on January...
Nov 20, 2018 08:00 am ET
Hancock Jaffe Updates Status of Application to INVIMA for First-In-Human VenoValve Trial in Colombia
Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, announced today that it has received an update from INVIMA (the Colombian equivalent of the U.S. FDA) in...
Nov 13, 2018 09:30 am ET
Hancock Jaffe Appoints Chris Sarner as Vice President of Regulatory Affairs and Quality Assurance
Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, today announced that Chris Sarner will be joining the company as its Vice President of Regulatory Affairs...
Oct 09, 2018 06:00 am ET
Hancock Jaffe Enters into Sponsored Research Agreement for CoreoGraft with World-Renowned Texas Heart Institute
Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, announced today that it has entered into a Sponsored Research Agreement with Texas Heart Institute for the...
Oct 02, 2018 06:00 am ET
Hancock Jaffe Appoints Three New Independent Directors
Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, announced today that it has appointed accomplished medical device professionals Dr. Francis Duhay and Dr....
Sep 28, 2018 06:00 am ET
Hancock Jaffe Laboratories to Present at The MicroCap Conference on October 2, 2018 in New York City
Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, today announced that it will present and meet with potential investors at The MicroCap Conference on October...
Sep 24, 2018 06:00 am ET
Hancock Jaffe Submits Application to INVIMA for First-In-Human VenoValve Trial in Colombia
Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, announced today that it has completed and submitted its application to INVIMA (the Colombian equivalent of...
Sep 20, 2018 09:30 am ET
Diamond Equity Research Initiates Coverage on Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI) with a Valuation of $6.60 Per Share
via NetworkWire – Diamond Equity Research, a leading equity research and corporate access firm with a focus on small capitalization public companies, has initiated coverage of Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI). The in-depth 21-page...
Sep 20, 2018 06:00 am ET
Hancock Jaffe to Present at Fourth Annual Robins Equity Research Roundup Conference
Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, announced today that it will present at the Fourth Annual Robins Equity Research Roundup, September 24, 25,...
Sep 17, 2018 06:00 am ET
New Study Confirms Significant Potential U.S. Market for Hancock Jaffe’s VenoValve®
Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, has commissioned a research report from The Sage Group, a research organization specializing in peripheral...
Sep 12, 2018 06:00 am ET
Hancock Jaffe Laboratories’ VenoValve Featured in Journal of Vascular Surgery Venous and Lymphatic Disorders as a Future Option for Treating Deep Vein Disease
Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, announced today that the Journal of Vascular Surgery Venous and Lymphatic Disorders published an article on...
Aug 09, 2018 07:00 am ET
Hancock Jaffe Laboratories Receives Medical Research Committee Approval for First-in-Human VenoValve Study
Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in bioprosthetic medical devices that establish improved standards of care for treating cardiac and vascular diseases, today announced that it has received approval for...
Jul 24, 2018 07:00 am ET
Hancock Jaffe Laboratories Receives Ethics Committee Approval for First-in-Human VenoValve Study
Hancock Jaffe Laboratories, Inc. (Nasdaq:HJLI) (Nasdaq:HJLIW), a company specializing in bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases, today announced that it has received approval...
Jul 13, 2018 06:18 pm ET
Hancock Jaffe Appoints Bob Rankin as Chief Financial Officer
Hancock Jaffe Laboratories, Inc. (Nasdaq:HJLI) (Nasdaq:HJLIW), a company specializing in bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases, today announced that Bob Rankin will be...
Jul 11, 2018 08:00 am ET
Hancock Jaffe Laboratories to Conduct Analysis for FDA Submission Package for Bioprosthetic Heart Valve
Hancock Jaffe Laboratories, Inc. (Nasdaq:HJLI) (Nasdaq:HJLIW), a company specializing in bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases, today announced that it has initiated an...
Jun 20, 2018 08:00 am ET
Hancock Jaffe Laboratories Selects Site for First-in-Human VenoValve Study
Hancock Jaffe Laboratories, Inc. (Nasdaq:HJLI) (Nasdaq:HJLIW), a company specializing in bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases, today announced that it has selected...
Jun 12, 2018 02:40 pm ET
Hancock Jaffe Laboratories, Inc. Announces Full Exercise of $1,125,000 Underwriter’s Over Allotment
Hancock Jaffe Laboratories, Inc. (Nasdaq:HJLI) (Nasdaq:HJLIW), a company specializing in bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases, today announced that Network 1 Financial...
Jun 05, 2018 01:19 pm ET
Hancock Jaffe Laboratories, Inc. Announces Closing of $7.5 Million Initial Public Offering
Hancock Jaffe Laboratories, Inc. (“HJLI”), a company specializing in bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases, today announced the closing of its previously announced initial...
May 31, 2018 07:30 am ET
Hancock Jaffe Laboratories, Inc. Announces Pricing of Initial Public Offering
Hancock Jaffe Laboratories, Inc. (“HJLI”), a company specializing in bioprosthetic medical devices to establish improved standards of care for treating cardiac and vascular diseases, today announced the pricing of its initial public offering of...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.